Search

Your search keyword '"Lombet, Jacques"' showing total 29 results
Start Over Author "Lombet, Jacques"
29 results on '"Lombet, Jacques"'

1. Refining genotype–phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants

Author

Eid, Loai Akram, Arbeiter, Klaus, Godefroid, Nathalie, Lombet, Jacques, De Mul, Aurélie, Feldkoetter, Markus, Zieg, Jakub, Grundmann, Franziska, Galiano, Matthias, Buchholz, Björn, Buescher, Anja, Häffner, Karsten, Gross, Oliver, Patzer, Ludwig, Oh, Jun, Haffner, Dieter, Bernhardt, Wanja, Schaefer, Susanne, Wygoda, Simone, Halbritter, Jan, Derichs, Ute, Klaus, Günter, Lechner, Felix, Ponsel, Sabine, König, Jens, Staude, Hagen, Wurm, Donald, Bald, Martin, Gessner, Michaela, Soliman, Neveen A., Ariceta, Gema, Gonzalez Rodriguez, Juan David, Ojeda, Francisco de la Cerda, Harambat, Jerome, Morin, Denis, Dossier, Claire, Dorval, Guillaume, Shroff, Rukshana, Stabouli, Stella, Hooman, Nakysa, Mencarelli, Francesca, Morello, William, Longo, Germana, Emma, Francesco, Jankauskiene, Augustina, Taranta-Janusz, Katarzyna, Zagozdzon, Ilona, Zachwieja, Katarzyna, Stanczyk, Malgorzata, Bienias, Beata, Litwin, Mieczyslaw, Morawiec-Knysak, Aurelia, Afonso, Alberto Caldas, Dunand, Oliver, Rachisan, Andreea, Miloševski-Lomić, Gordana, Papizh, Svetlana, Rus, Rina, Jilani, Houweyda, Atmis, Bahriye, Duzova, Ali, Soylu, Alper, Candan, Cengiz, Caliskan, Salim, Yilmaz, Alev, Gökce, İbrahim, Akinci, Nurver, Mir, Sevgi, Dursun, Ismail, Tabel, Yilmaz, Nalcacioglu, Hulya, Burgmaier, Kathrin, Brinker, Leonie, Erger, Florian, Beck, Bodo B., Benz, Marcus R., Bergmann, Carsten, Boyer, Olivia, Collard, Laure, Dafinger, Claudia, Fila, Marc, Kowalewska, Claudia, Lange-Sperandio, Bärbel, Massella, Laura, Mastrangelo, Antonio, Mekahli, Djalila, Miklaszewska, Monika, Ortiz-Bruechle, Nadina, Prikhodina, Larisa, Ranchin, Bruno, Ranguelov, Nadejda, Schild, Raphael, Seeman, Tomas, Sever, Lale, Sikora, Przemyslaw, Szczepanska, Maria, Teixeira, Ana, Thumfart, Julia, Uetz, Barbara, Weber, Lutz Thorsten, Wühl, Elke, Zerres, Klaus, Dötsch, Jörg, Schaefer, Franz, and Liebau, Max Christoph

Published
2021
Full Text
View/download PDF

2. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium

Author

Boemer, François, Caberg, Jean-Hubert, Beckers, Pablo, Dideberg, Vinciane, di Fiore, Samantha, Bours, Vincent, Marie, Sandrine, Dewulf, Joseph, Marcelis, Lionel, Deconinck, Nicolas, Daron, Aurore, Blasco-Perez, Laura, Tizzano, Eduardo, Hiligsmann, Mickaël, Lombet, Jacques, Pereira, Tatiana, Lopez-Granados, Lucia, Shalchian-Tehran, Sarvnaz, van Assche, Véronique, Willems, Arabelle, Huybrechts, Sofie, Mast, Bénédicte, van Olden, Rudolf, Dangouloff, Tamara, and Servais, Laurent

Published
2021
Full Text
View/download PDF

3. Risk Factors for Early Dialysis Dependency in Autosomal Recessive Polycystic Kidney Disease

Author

Ranguelov, Nadejda, Godefroid, Nathalie, Collard, Laure, Lombet, Jacques, Maquet, Julie, Schalk, Gesa, Querfeld, Uwe, Beck, Bodo B., Benzing, Thomas, Buettner, Reinhard, Grundmann, Franziska, Kurschat, Christine, Benz, Kerstin, Tzschoppe, Anja, Buchholz, Björn, Buescher, Rainer, Häffner, Karsten, Pohl, Martin, Gross, Oliver, Krügel, Jenny, Stock, Johanna, Patzer, Ludwig, Oh, Jun, Bernhardt, Wanja, Doyon, Anke, Vinke, Tobias, Sander, Anja, Henn, Michael, Derichs, Ute, Beetz, Rolf, Jeck, Nikola, Lange-Sperandio, Bärbel, Ponsel, Sabine, Kusser, Franziska, Uetz, Barbara, Benz, Marcus, Schmidt, Silke, Huppertz-Kessler, Christina, Kranz, Birgitta, Titieni, Andrea, Wurm, Donald, Leichter, Heinz E., Bald, Martin, Billing, Heiko, Nabhan, Marwa M., Lara, Luis Enrique, Papachristou, Fotios, Emma, Francesco, Cerkauskiene, Rimante, Azukaitis, Karolis, Wasilewska, Anna, Balasz-Chmielewska, Irena, Miklaszewska, Monika, Tkaczyk, Marcin, Sikora, Przemyslaw, Zaniew, Marcin, Niemirska, Ania, Antoniewicz, Jolanta, Lesiak, Justyna, Afonso, Alberto Caldas, Teixeira, Ana, Milosevski-Lomic, Gordana, Paripović, Dusan, Peco-Antic, Amira, Papizh, Svetlana, Bayazit, Aysun Karabay, Anarat, Ali, Soylu, Alper, Kavukcu, Salih, Candan, Cengiz, Caliskan, Salim, Canpolat, Nur, Emre, Sevinc, Alpay, Harika, Akinci, Nurver, Conkar, Secil, Poyrazoglu, Hakan M., Dusunsel, Ruhan, Burgmaier, Kathrin, Kunzmann, Kevin, Ariceta, Gema, Bergmann, Carsten, Buescher, Anja Katrin, Burgmaier, Mathias, Dursun, Ismail, Duzova, Ali, Eid, Loai, Erger, Florian, Feldkoetter, Markus, Galiano, Matthias, Geßner, Michaela, Goebel, Heike, Gokce, Ibrahim, Haffner, Dieter, Hooman, Nakysa, Hoppe, Bernd, Jankauskiene, Augustina, Klaus, Guenter, König, Jens, Litwin, Mieczyslaw, Massella, Laura, Mekahli, Djalila, Melek, Engin, Mir, Sevgi, Pape, Lars, Prikhodina, Larisa, Ranchin, Bruno, Schild, Raphael, Seeman, Tomas, Sever, Lale, Shroff, Rukshana, Soliman, Neveen A., Stabouli, Stella, Stanczyk, Malgorzata, Tabel, Yilmaz, Taranta-Janusz, Katarzyna, Testa, Sara, Thumfart, Julia, Topaloglu, Rezan, Weber, Lutz Thorsten, Wicher, Dorota, Wühl, Elke, Wygoda, Simone, Yilmaz, Alev, Zachwieja, Katarzyna, Zagozdzon, Ilona, Zerres, Klaus, Dötsch, Jörg, Schaefer, Franz, and Liebau, Max Christoph

Published
2018
Full Text
View/download PDF

4. Refining genotype–phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants

Author

Burgmaier, Kathrin, primary, Brinker, Leonie, additional, Erger, Florian, additional, Beck, Bodo B., additional, Benz, Marcus R., additional, Bergmann, Carsten, additional, Boyer, Olivia, additional, Collard, Laure, additional, Dafinger, Claudia, additional, Fila, Marc, additional, Kowalewska, Claudia, additional, Lange-Sperandio, Bärbel, additional, Massella, Laura, additional, Mastrangelo, Antonio, additional, Mekahli, Djalila, additional, Miklaszewska, Monika, additional, Ortiz-Bruechle, Nadina, additional, Patzer, Ludwig, additional, Prikhodina, Larisa, additional, Ranchin, Bruno, additional, Ranguelov, Nadejda, additional, Schild, Raphael, additional, Seeman, Tomas, additional, Sever, Lale, additional, Sikora, Przemyslaw, additional, Szczepanska, Maria, additional, Teixeira, Ana, additional, Thumfart, Julia, additional, Uetz, Barbara, additional, Weber, Lutz Thorsten, additional, Wühl, Elke, additional, Zerres, Klaus, additional, Dötsch, Jörg, additional, Schaefer, Franz, additional, Liebau, Max Christoph, additional, Eid, Loai Akram, additional, Arbeiter, Klaus, additional, Godefroid, Nathalie, additional, Lombet, Jacques, additional, De Mul, Aurélie, additional, Feldkoetter, Markus, additional, Zieg, Jakub, additional, Grundmann, Franziska, additional, Galiano, Matthias, additional, Buchholz, Björn, additional, Buescher, Anja, additional, Häffner, Karsten, additional, Gross, Oliver, additional, Oh, Jun, additional, Haffner, Dieter, additional, Bernhardt, Wanja, additional, Schaefer, Susanne, additional, Wygoda, Simone, additional, Halbritter, Jan, additional, Derichs, Ute, additional, Klaus, Günter, additional, Lechner, Felix, additional, Ponsel, Sabine, additional, König, Jens, additional, Staude, Hagen, additional, Wurm, Donald, additional, Bald, Martin, additional, Gessner, Michaela, additional, Soliman, Neveen A., additional, Ariceta, Gema, additional, Gonzalez Rodriguez, Juan David, additional, Ojeda, Francisco de la Cerda, additional, Harambat, Jerome, additional, Morin, Denis, additional, Dossier, Claire, additional, Dorval, Guillaume, additional, Shroff, Rukshana, additional, Stabouli, Stella, additional, Hooman, Nakysa, additional, Mencarelli, Francesca, additional, Morello, William, additional, Longo, Germana, additional, Emma, Francesco, additional, Jankauskiene, Augustina, additional, Taranta-Janusz, Katarzyna, additional, Zagozdzon, Ilona, additional, Zachwieja, Katarzyna, additional, Stanczyk, Malgorzata, additional, Bienias, Beata, additional, Litwin, Mieczyslaw, additional, Morawiec-Knysak, Aurelia, additional, Afonso, Alberto Caldas, additional, Dunand, Oliver, additional, Rachisan, Andreea, additional, Miloševski-Lomić, Gordana, additional, Papizh, Svetlana, additional, Rus, Rina, additional, Jilani, Houweyda, additional, Atmis, Bahriye, additional, Duzova, Ali, additional, Soylu, Alper, additional, Candan, Cengiz, additional, Caliskan, Salim, additional, Yilmaz, Alev, additional, Gökce, İbrahim, additional, Akinci, Nurver, additional, Mir, Sevgi, additional, Dursun, Ismail, additional, Tabel, Yilmaz, additional, and Nalcacioglu, Hulya, additional

Published
2021
Full Text
View/download PDF

5. Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern Belgium.

Author

UCL - SSS/DDUV - Institut de Duve, UCL - (SLuc) Service de biochimie médicale, Boemer, François, Caberg, Jean-Hubert, Beckers, Pablo, Dideberg, Vinciane, di Fiore, Samantha, Bours, Vincent, Marie, Sandrine, Dewulf, Joseph, Marcelis, Lionel, Deconinck, Nicolas, Daron, Aurore, Blasco-Perez, Laura, Tizzano, Eduardo, Hiligsmann, Mickaël, Lombet, Jacques, Pereira, Tatiana, Lopez-Granados, Lucia, Shalchian-Tehran, Sarvnaz, van Assche, Véronique, Willems, Arabelle, Huybrechts, Sofie, Mast, Bénédicte, van Olden, Rudolf, Dangouloff, Tamara, Servais, Laurent, UCL - SSS/DDUV - Institut de Duve, UCL - (SLuc) Service de biochimie médicale, Boemer, François, Caberg, Jean-Hubert, Beckers, Pablo, Dideberg, Vinciane, di Fiore, Samantha, Bours, Vincent, Marie, Sandrine, Dewulf, Joseph, Marcelis, Lionel, Deconinck, Nicolas, Daron, Aurore, Blasco-Perez, Laura, Tizzano, Eduardo, Hiligsmann, Mickaël, Lombet, Jacques, Pereira, Tatiana, Lopez-Granados, Lucia, Shalchian-Tehran, Sarvnaz, van Assche, Véronique, Willems, Arabelle, Huybrechts, Sofie, Mast, Bénédicte, van Olden, Rudolf, Dangouloff, Tamara, and Servais, Laurent

Abstract

Three new therapies for spinal muscular atrophy (SMA) have been approved by the United States Food and Drug Administration and the European Medicines Agency since 2016. Although these new therapies improve the quality of life of patients who are symptomatic at first treatment, administration before the onset of symptoms is significantly more effective. As a consequence, newborn screening programs have been initiated in several countries. In 2018, we launched a 3-year pilot program to screen newborns for SMA in the Belgian region of Liège. This program was rapidly expanding to all of Southern Belgium, a region of approximately 55,000 births annually. During the pilot program, 136,339 neonates were tested for deletion of exon 7 of SMN1, the most common cause of SMA. Nine SMA cases with homozygous deletion were identified through this screen. Another patient was identified after presenting with symptoms and was shown to be heterozygous for the SMN1 exon 7 deletion and a point mutation on the opposite allele. These ten patients were treated. The pilot program has now successfully transitioned into the official neonatal screening program in Southern Belgium. The lessons learned during implementation of this pilot program are reported.

Published
2021

6. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium

Author

UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de pédiatrie générale, Laurent, Michaël R., De Schepper, Jean, Trouet, Dominique, Godefroid, Nathalie, Boros, Emese, Heinrichs, Claudine, Bravenboer, Bert, Velkeniers, Brigitte, Lammens, Johan, Harvengt, Pol, Cavalier, Etienne, Kaux, Jean-François, Lombet, Jacques, De Waele, Kathleen, Verroken, Charlotte, van Hoeck, Koenraad, Mortier, Geert R., Levtchenko, Elena, Vande Walle, Johan, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de pédiatrie générale, Laurent, Michaël R., De Schepper, Jean, Trouet, Dominique, Godefroid, Nathalie, Boros, Emese, Heinrichs, Claudine, Bravenboer, Bert, Velkeniers, Brigitte, Lammens, Johan, Harvengt, Pol, Cavalier, Etienne, Kaux, Jean-François, Lombet, Jacques, De Waele, Kathleen, Verroken, Charlotte, van Hoeck, Koenraad, Mortier, Geert R., Levtchenko, Elena, and Vande Walle, Johan

Abstract

X-linked hypophosphatemia (XLH) is the most common genetic form of hypophosphatemic rickets and osteomalacia. In this disease, mutations in the PHEX gene lead to elevated levels of the hormone fibroblast growth factor 23 (FGF23), resulting in renal phosphate wasting and impaired skeletal and dental mineralization. Recently,international guidelines for the diagnosis and treatment of this condition have been published. However, more specific recommendations are needed to provide guidance at the national level, considering resource availability and health economic aspects. A national multidisciplinary group of Belgian experts convened to discuss translation of international best available evidence into locally feasible consensus recommendations.Patients with XLH may present to a wide array of primary, secondary and tertiary care physicians, among whom awareness of the disease should be raised. XLH has a very broad differential-diagnosis for which clinical features, biochemical and genetic testing in centers of expertise are recommended. Optimal care requires a multidisciplinary approach, guided by an expert in metabolic bone diseases and involving (according to the individual patient’s needs) pediatric and adult medical specialties and paramedical caregivers, including but not limited to general practitioners, dentists, radiologists and orthopedic surgeons. In children with severe or refractory symptoms, FGF23 inhibition using burosumab may provide superior outcomes compared to conventional medical therapy with phosphate supplements and active vitamin D analogues. Burosumab has also demonstrated promising results in adults on certain clinical outcomes such as pseudofractures. In summary, this work outlines recommendations for clinicians and policymakers, with a vision for improving the diagnostic and therapeutic landscape for XLH patients in Belgium.

Published
2021

7. Corrigendum: Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

Author

UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de pédiatrie générale, Laurent, Michaël R, De Schepper, Jean, Trouet, Dominique, Godefroid, Nathalie, Boros, Emese, Heinrichs, Claudine, Bravenboer, Bert, Velkeniers, Brigitte, Lammens, Johan, Harvengt, Pol, Cavalier, Etienne, Kaux, Jean-François, Lombet, Jacques, De Waele, Kathleen, Verroken, Charlotte, van Hoeck, Koenraad, Mortier, Geert R, Levtchenko, Elena, Vande Walle, Johan, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service de pédiatrie générale, Laurent, Michaël R, De Schepper, Jean, Trouet, Dominique, Godefroid, Nathalie, Boros, Emese, Heinrichs, Claudine, Bravenboer, Bert, Velkeniers, Brigitte, Lammens, Johan, Harvengt, Pol, Cavalier, Etienne, Kaux, Jean-François, Lombet, Jacques, De Waele, Kathleen, Verroken, Charlotte, van Hoeck, Koenraad, Mortier, Geert R, Levtchenko, Elena, and Vande Walle, Johan

Abstract

[This corrects the article DOI: 10.3389/fendo.2021.641543.].

Published
2021

8. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium

Author

Laurent, Michaël M.R., De Schepper, Jean, Trouet, Dominique, Godefroid, Nathalie, Boros, EMESE, Heinrichs, Claudine, Bravenboer, Bert, Velkeniers, Brigitte, Lammens, Johan, Harvengt, Pol, Cavalier, Etienne, Kaux, Jean François, Lombet, Jacques, De Waele, Kathleen, Verroken, Charlotte, Van Hoeck, Koenraad, Mortier, Geert, Levtchenko, Elena N., Schurmans, Thierry, Laurent, Michaël M.R., De Schepper, Jean, Trouet, Dominique, Godefroid, Nathalie, Boros, EMESE, Heinrichs, Claudine, Bravenboer, Bert, Velkeniers, Brigitte, Lammens, Johan, Harvengt, Pol, Cavalier, Etienne, Kaux, Jean François, Lombet, Jacques, De Waele, Kathleen, Verroken, Charlotte, Van Hoeck, Koenraad, Mortier, Geert, Levtchenko, Elena N., and Schurmans, Thierry

Abstract

X-linked hypophosphatemia (XLH) is the most common genetic form of hypophosphatemic rickets and osteomalacia. In this disease, mutations in the PHEX gene lead to elevated levels of the hormone fibroblast growth factor 23 (FGF23), resulting in renal phosphate wasting and impaired skeletal and dental mineralization. Recently, international guidelines for the diagnosis and treatment of this condition have been published. However, more specific recommendations are needed to provide guidance at the national level, considering resource availability and health economic aspects. A national multidisciplinary group of Belgian experts convened to discuss translation of international best available evidence into locally feasible consensus recommendations. Patients with XLH may present to a wide array of primary, secondary and tertiary care physicians, among whom awareness of the disease should be raised. XLH has a very broad differential-diagnosis for which clinical features, biochemical and genetic testing in centers of expertise are recommended. Optimal care requires a multidisciplinary approach, guided by an expert in metabolic bone diseases and involving (according to the individual patient’s needs) pediatric and adult medical specialties and paramedical caregivers, including but not limited to general practitioners, dentists, radiologists and orthopedic surgeons. In children with severe or refractory symptoms, FGF23 inhibition using burosumab may provide superior outcomes compared to conventional medical therapy with phosphate supplements and active vitamin D analogues. Burosumab has also demonstrated promising results in adults on certain clinical outcomes such as pseudofractures. In summary, this work outlines recommendations for clinicians and policymakers, with a vision for improving the diagnostic and therapeutic landscape for XLH patients in Belgium., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2021

9. Corrigendum: Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium

Author

Laurent, Michaël R., primary, De Schepper, Jean, additional, Trouet, Dominique, additional, Godefroid, Nathalie, additional, Boros, Emese, additional, Heinrichs, Claudine, additional, Bravenboer, Bert, additional, Velkeniers, Brigitte, additional, Lammens, Johan, additional, Harvengt, Pol, additional, Cavalier, Etienne, additional, Kaux, Jean-François, additional, Lombet, Jacques, additional, De Waele, Kathleen, additional, Verroken, Charlotte, additional, van Hoeck, Koenraad, additional, Mortier, Geert R., additional, Levtchenko, Elena, additional, and Vande Walle, Johan, additional

Published
2021
Full Text
View/download PDF

10. Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium

Author

Laurent, Michaël R., primary, De Schepper, Jean, additional, Trouet, Dominique, additional, Godefroid, Nathalie, additional, Boros, Emese, additional, Heinrichs, Claudine, additional, Bravenboer, Bert, additional, Velkeniers, Brigitte, additional, Lammens, Johan, additional, Harvengt, Pol, additional, Cavalier, Etienne, additional, Kaux, Jean-François, additional, Lombet, Jacques, additional, De Waele, Kathleen, additional, Verroken, Charlotte, additional, van Hoeck, Koenraad, additional, Mortier, Geert R., additional, Levtchenko, Elena, additional, and Vande Walle, Johan, additional

Published
2021
Full Text
View/download PDF

11. The EPIBEL study: outcomes to discharge from hospital for extremely preterm infants in Belgium

Author

Vanhaesebrouck, Piet, Allegaert, Karel, Bottu, Jean, Debauche, Christian, Devlieger, Hugo, Docx, Martine, Francois, Anne, Haumont, Dominique, Lombet, Jacques, Rigo, Jacques, Smets, Koenraad, Vanherreweghe, Inge, Van Overmeire, Bart, and Van Reempts, Patrick

Subjects
Hospitals -- Admission and discharge, Infants (Premature) -- Health aspects
Abstract

Objective. To determine mortality and morbidity at discharge from the hospital of a large population-based cohort of infants who were born at [less than or equal to] 26 weeks' gestation. Methods. Perinatal data were collected on extremely preterm infants who were alive at the onset of labor and born between January 1, 1999, and December 31, 2000, in all 19 Belgian perinatal centers. Results. A total of 525 infants were recorded. Life-supporting care was provided to 322 liveborn infants, 303 of whom were admitted for intensive care. The overall survival rate of liveborn infants was 54%. Of the infants who were alive at the age of 7 days, 82% survived to discharge. Vaginal delivery, shorter gestation, air leak, longer ventilator dependence, and higher initial oxygen need all were independently associated with death; gender, plurality, and surfactant therapy were not. Among the 175 survivors, 63% had 1 or more of the 3 major adverse outcome variables at the time of discharge (serious neuromorbidity, chronic lung disease at 36 weeks' postmenstrual age, or treated retinopathy of prematurity). The chance of survival free from serious neonatal morbidity at the time of hospital discharge was Conclusions. If for the time being prolongation of pregnancy is unsuccessful, then outcome perspectives should be discussed and treatment options including nonintervention explicitly be made available to parents of infants of, ABBREVIATIONS. BW, birth weight; GA, gestational age; EPT, extremely preterm; NICU, neonatal intensive care unit; OR, odds ratio; CI, confidence interval; ROP, retinopathy of prematurity; CLD, chronic lung disease; CS, [...]

Published
2004

14. Risk Factors for Early Dialysis Dependency in Autosomal Recessive Polycystic Kidney Disease

Author

Burgmaier, Kathrin, primary, Kunzmann, Kevin, additional, Ariceta, Gema, additional, Bergmann, Carsten, additional, Buescher, Anja Katrin, additional, Burgmaier, Mathias, additional, Dursun, Ismail, additional, Duzova, Ali, additional, Eid, Loai, additional, Erger, Florian, additional, Feldkoetter, Markus, additional, Galiano, Matthias, additional, Geßner, Michaela, additional, Goebel, Heike, additional, Gokce, Ibrahim, additional, Haffner, Dieter, additional, Hooman, Nakysa, additional, Hoppe, Bernd, additional, Jankauskiene, Augustina, additional, Klaus, Guenter, additional, König, Jens, additional, Litwin, Mieczyslaw, additional, Massella, Laura, additional, Mekahli, Djalila, additional, Melek, Engin, additional, Mir, Sevgi, additional, Pape, Lars, additional, Prikhodina, Larisa, additional, Ranchin, Bruno, additional, Schild, Raphael, additional, Seeman, Tomas, additional, Sever, Lale, additional, Shroff, Rukshana, additional, Soliman, Neveen A., additional, Stabouli, Stella, additional, Stanczyk, Malgorzata, additional, Tabel, Yilmaz, additional, Taranta-Janusz, Katarzyna, additional, Testa, Sara, additional, Thumfart, Julia, additional, Topaloglu, Rezan, additional, Weber, Lutz Thorsten, additional, Wicher, Dorota, additional, Wühl, Elke, additional, Wygoda, Simone, additional, Yilmaz, Alev, additional, Zachwieja, Katarzyna, additional, Zagozdzon, Ilona, additional, Zerres, Klaus, additional, Dötsch, Jörg, additional, Schaefer, Franz, additional, Liebau, Max Christoph, additional, Ranguelov, Nadejda, additional, Godefroid, Nathalie, additional, Collard, Laure, additional, Lombet, Jacques, additional, Maquet, Julie, additional, Schalk, Gesa, additional, Querfeld, Uwe, additional, Beck, Bodo B., additional, Benzing, Thomas, additional, Buettner, Reinhard, additional, Grundmann, Franziska, additional, Kurschat, Christine, additional, Benz, Kerstin, additional, Tzschoppe, Anja, additional, Buchholz, Björn, additional, Buescher, Rainer, additional, Häffner, Karsten, additional, Pohl, Martin, additional, Gross, Oliver, additional, Krügel, Jenny, additional, Stock, Johanna, additional, Patzer, Ludwig, additional, Oh, Jun, additional, Bernhardt, Wanja, additional, Doyon, Anke, additional, Vinke, Tobias, additional, Sander, Anja, additional, Henn, Michael, additional, Derichs, Ute, additional, Beetz, Rolf, additional, Jeck, Nikola, additional, Lange-Sperandio, Bärbel, additional, Ponsel, Sabine, additional, Kusser, Franziska, additional, Uetz, Barbara, additional, Benz, Marcus, additional, Schmidt, Silke, additional, Huppertz-Kessler, Christina, additional, Kranz, Birgitta, additional, Titieni, Andrea, additional, Wurm, Donald, additional, Leichter, Heinz E., additional, Bald, Martin, additional, Billing, Heiko, additional, Nabhan, Marwa M., additional, Lara, Luis Enrique, additional, Papachristou, Fotios, additional, Emma, Francesco, additional, Cerkauskiene, Rimante, additional, Azukaitis, Karolis, additional, Wasilewska, Anna, additional, Balasz-Chmielewska, Irena, additional, Miklaszewska, Monika, additional, Tkaczyk, Marcin, additional, Sikora, Przemyslaw, additional, Zaniew, Marcin, additional, Niemirska, Ania, additional, Antoniewicz, Jolanta, additional, Lesiak, Justyna, additional, Afonso, Alberto Caldas, additional, Teixeira, Ana, additional, Milosevski-Lomic, Gordana, additional, Paripović, Dusan, additional, Peco-Antic, Amira, additional, Papizh, Svetlana, additional, Bayazit, Aysun Karabay, additional, Anarat, Ali, additional, Soylu, Alper, additional, Kavukcu, Salih, additional, Candan, Cengiz, additional, Caliskan, Salim, additional, Canpolat, Nur, additional, Emre, Sevinc, additional, Alpay, Harika, additional, Akinci, Nurver, additional, Conkar, Secil, additional, Poyrazoglu, Hakan M., additional, and Dusunsel, Ruhan, additional

Published
2018
Full Text
View/download PDF

17. Prévention de l'infection respiratoire à VRS par immunoglobulines monoclonales spécifiques (palivizumab, Synagis).

Author

De Halleux, Véronique, Lombet, Jacques, Rigo, Jacques, De Halleux, Véronique, Lombet, Jacques, and Rigo, Jacques

Abstract

Respiratory syncytial virus (RSV) is a serious pathogen causing significant morbidity, especially in premature infants and infants with chronic lung disease or significant congenital heart disease. There is no specific treatment for RSV infection and the therapy is essentially supportive. Therefore, prophylaxis is the best strategy against RSV disease. Passive immunization with monoclonal antibodies (palivizumab) provides protection against severe RSV infection and significantly reduces hospitalizations in high-risk childrens. However, palizumab is an expensive drug and its use should be reserved for children at the highest risk of severe RSV disease., English Abstract, Journal Article, Review, info:eu-repo/semantics/published

Published
2007

18. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection

Author

Lacaze-Masmonteil, Thierry, Seidenberg, Juergen, Mitchell, Ian, Cossey, Veerle, Cihar, Martin, Csader, Michal, Baarsma, Rienk, Valido, Marques, Pollack, Paul P.F., Groothuis, Jessie J.R., Allegaert, Karel, Lombet, Jacques, Haumont, Dominique, Plaskie, Katleen, Davies, Dele Dele H.D., Sauve, Reg R.S., Langley, Joanne J.M., Liska, Karel, Andre, Patrick, Lequien, Pierre, Kacet, Nadine, Lapeyre, Fabrice, Wickenburg-Ennen, Barbara, Nolte, Helga, Harding, Peter Andreas, Ramos, Sandra, Carolino, Margarida, Marques, Antónia, Lacaze-Masmonteil, Thierry, Seidenberg, Juergen, Mitchell, Ian, Cossey, Veerle, Cihar, Martin, Csader, Michal, Baarsma, Rienk, Valido, Marques, Pollack, Paul P.F., Groothuis, Jessie J.R., Allegaert, Karel, Lombet, Jacques, Haumont, Dominique, Plaskie, Katleen, Davies, Dele Dele H.D., Sauve, Reg R.S., Langley, Joanne J.M., Liska, Karel, Andre, Patrick, Lequien, Pierre, Kacet, Nadine, Lapeyre, Fabrice, Wickenburg-Ennen, Barbara, Nolte, Helga, Harding, Peter Andreas, Ramos, Sandra, Carolino, Margarida, and Marques, Antónia

Abstract

Background: Palivizumab reduces respiratory syncytial virus (RSV) hospitalisations in high-risk infants. Those with severe bronchopulmonary dysplasia may require two seasons of prophylaxis. There is concern that this humanised antibody might cause an adverse immune response in a second season of use. Objective: To evaluate and compare the occurrence of anti-palivizumab antibodies and clinical adverse events in subjects receiving monthly palivizumab injections for a first and second season, and to assess frequency and severity of RSV disease in the two groups. Design and Patients: Subjects aged ≤2 years at severe risk for RSV disease were designated as first season (no previous palivizumab exposure) or second season subjects (received palivizumab in previous RSV season). Palivizumab injections (15 mg/kg) were administered monthly for up to 5 months. Anti-palivizumab antibody titres and serum palivizumab concentrations were measured; adverse events were recorded. Results: No first (n = 71) or second (n = 63) season subjects experienced a significant anti-palivizumab antibody response (titre ≥1:80). Serum palivizumab concentrations were similar for the two groups. Nine (12.7%) first season and 8 (12.7%) second season subjects experienced one or more serious adverse events; most were respiratory and all were considered to be not or probably not related to palivizumab. No deaths occurred during the study. Conclusions: Monthly palivizumab injections were not associated with adverse immune responses or adverse events in young children receiving palivizumab for one or two seasons. Children receiving palivizumab for a second season did not experience more severe adverse events than those receiving it for the first time., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2003

28. Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux.

Author

Morello W, Baskin E, Jankauskiene A, Yalcinkaya F, Zurowska A, Puccio G, Serafinelli J, La Manna A, Krzemień G, Pennesi M, La Scola C, Becherucci F, Brugnara M, Yuksel S, Mekahli D, Chimenz R, De Palma D, Zucchetta P, Vajauskas D, Drozdz D, Szczepanska M, Caliskan S, Lombet J, Minoli DG, Guarino S, Gulleroglu K, Ruzgiene D, Szmigielska A, Barbi E, Ozcakar ZB, Kranz A, Pasini A, Materassi M, De Rechter S, Ariceta G, Weber LT, Marzuillo P, Alberici I, Taranta-Janusz K, Caldas Afonso A, Tkaczyk M, Català M, Cabrera Sevilla JE, Mehls O, Schaefer F, and Montini G

Subjects
Female, Humans, Infant, Male, Glomerulonephritis, Intention to Treat Analysis, Drug Resistance, Bacterial drug effects, Antibiotic Prophylaxis adverse effects, Antibiotic Prophylaxis methods, Vesico-Ureteral Reflux complications, Vesico-Ureteral Reflux drug therapy, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents therapeutic use, Urinary Tract Infections etiology, Urinary Tract Infections microbiology, Urinary Tract Infections prevention & control
Abstract

Background: The efficacy of continuous antibiotic prophylaxis in preventing urinary tract infection (UTI) in infants with grade III, IV, or V vesicoureteral reflux is controversial., Methods: In this investigator-initiated, randomized, open-label trial performed in 39 European centers, we randomly assigned infants 1 to 5 months of age with grade III, IV, or V vesicoureteral reflux and no previous UTIs to receive continuous antibiotic prophylaxis (prophylaxis group) or no treatment (untreated group) for 24 months. The primary outcome was the occurrence of the first UTI during the trial period. Secondary outcomes included new kidney scarring and the estimated glomerular filtration rate (GFR) at 24 months., Results: A total of 292 participants underwent randomization (146 per group). Approximately 75% of the participants were male; the median age was 3 months, and 235 participants (80.5%) had grade IV or V vesicoureteral reflux. In the intention-to-treat analysis, a first UTI occurred in 31 participants (21.2%) in the prophylaxis group and in 52 participants (35.6%) in the untreated group (hazard ratio, 0.55; 95% confidence interval [CI], 0.35 to 0.86; P = 0.008); the number needed to treat for 2 years to prevent one UTI was 7 children (95% CI, 4 to 29). Among untreated participants, 64.4% had no UTI during the trial. The incidence of new kidney scars and the estimated GFR at 24 months did not differ substantially between the two groups. Pseudomonas species, other non- Escherichia coli organisms, and antibiotic resistance were more common in UTI isolates obtained from participants in the prophylaxis group than in isolates obtained from those in the untreated group. Serious adverse events were similar in the two groups., Conclusions: In infants with grade III, IV, or V vesicoureteral reflux and no previous UTIs, continuous antibiotic prophylaxis provided a small but significant benefit in preventing a first UTI despite an increased occurrence of non- E. coli organisms and antibiotic resistance. (Funded by the Italian Ministry of Health and others; PREDICT ClinicalTrials.gov number, NCT02021006; EudraCT number, 2013-000309-21.)., (Copyright © 2023 Massachusetts Medical Society.)

Published
2023
Full Text
View/download PDF

29. Heart rate response profiles to tilting in healthy and unhealthy neonates.

Author

Massin MM, Maeyns K, Lombet J, Rigo J, and Gerard P

Subjects
Bradycardia diagnosis, Female, Heroin Dependence, Humans, Infant, Newborn, Infant, Premature, Male, Heart Rate, Tilt-Table Test methods
Abstract

Background: Clinical observations suggest the immaturity of the neonate's ability to respond appropriately to cardio-respiratory challenges and tilt test could help in detecting autonomic dysfunction in neonates., Material/methods: Heart rate (HR) responses following a 45 degrees head-up tilt during sleep were measured within the first week of adjusted age in 7 healthy full-term neonates, 7 healthy preterm infants and 5 neonates with abstinence syndrome., Results: The tilt and the return to the horizontal position generally provoked a sustained or transient tachycardia, or a flat response in healthy full-term neonates and in preterm neonates, but a sustained or transient bradycardia in neonates with abstinence syndrome., Conclusions: When compared to previous studies in older infants, our data point to the immaturity of the neonate's ability to respond appropriately to cardio-respiratory challenges. No difference is noted between full-term and preterm neonates. The altered HR response in neonates with abstinence syndrome suggests an autonomic dysregulation in this group.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results